Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics Inc (CGTX) is a clinical-stage biopharmaceutical company pioneering treatments for neurodegenerative disorders through its sigma-2 receptor modulator platform. This page serves as the definitive source for verified news and official announcements related to CGTX's research, clinical trials, and corporate developments.
Investors and industry observers will find timely updates on clinical progress for lead candidate CT1812, financial disclosures, and strategic collaborations with research institutions. The curated content includes press releases on trial milestones, peer-reviewed study publications, and regulatory filings, providing essential insights for informed decision-making.
All materials are organized to help users efficiently track developments in Alzheimer's disease, dementia with Lewy bodies, and retinal disorder research. Bookmark this page to maintain current awareness of CGTX's scientific advancements and corporate initiatives within the competitive neurodegenerative therapeutics landscape.
Cognition Therapeutics (NASDAQ: CGTX) has reported its financial results for Q4 and full-year 2024, highlighting significant progress in its neurodegenerative disorder treatments. The company's lead candidate, zervimesine (CT1812), showed promising results in two Phase 2 studies:
The SHIMMER study in Dementia with Lewy Bodies (DLB) demonstrated up to 91% slowing compared to placebo across behavioral, functional, cognitive, and movement measures. The SHINE study in Alzheimer's disease revealed near-total preservation of cognition in patients with lower p-tau217 levels.
Financial highlights include:
- Cash position of $25.0 million as of December 31, 2024
- $50.0 million in remaining NIA grant funds
- R&D expenses increased to $41.7 million from $37.2 million in 2023
- Net loss of $34.0 million ($0.86 per share)
The company plans to advance zervimesine into Phase 3 trials for both DLB and Alzheimer's, with FDA meetings expected in early Q2 2025. Cash runway extends into Q4 2025.
Cognition Therapeutics (Nasdaq: CGTX), a clinical stage company focused on neurodegenerative disorders treatment, has announced it will release its Q4 and full-year 2024 financial results on Thursday, March 20, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day, during which management will review financial and operating results and provide a business update.
Cognition Therapeutics (CGTX) has received a notification from Nasdaq regarding its transfer from The Nasdaq Global Market to The Nasdaq Capital Market, effective March 14, 2025. This follows the company's failure to maintain a minimum bid price of $1.00 per share over 30 consecutive business days, as initially notified on September 12, 2024.
The company has been granted an additional 180 calendar days until September 8, 2025, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. If compliance is not achieved naturally, CGTX may seek stockholder approval for a reverse stock split, which would need to be implemented at least 10 business days before the compliance period ends.
Cognition Therapeutics (NASDAQ: CGTX), a clinical stage company focused on neurodegenerative disorders, has announced that President and CEO Lisa Ricciardi will deliver a live presentation at the Life Sciences Virtual Investor Conference on March 13, 2025, at 9:30 a.m. ET.
The presentation will outline the company's 2025 plans for advancing zervimesine (CT1812) in Alzheimer's disease and dementia with Lewy bodies, following positive Phase 2 data readouts. The interactive online event will feature real-time Q&A with the management team.
Investors unable to attend the live event can access an archived webcast through Cognition's Investor Relations webpage. Pre-registration is recommended for interested participants at www.virtualinvestorconferences.com.
Cognition Therapeutics (Nasdaq: CGTX) has published research in Nature Scientific Reports demonstrating the potential of their drug candidate zervimesine (CT1812) in treating dry age-related macular degeneration (dry AMD).
The research comprised multiple studies, including analysis of cerebrospinal fluid from Alzheimer's disease clinical trials and collaborative in vitro research with the University of Southampton. The studies revealed that zervimesine treatment altered proteins and pathways associated with geographic atrophy and macular degeneration.
Laboratory tests showed that zervimesine could rescue impaired cellular processes in retinal pigment epithelial (RPE) cells, which are important for breaking down photoreceptor debris and maintaining sight. While the results support zervimesine's potential in treating dry AMD, the company will currently focus its financial resources on Alzheimer's disease and dementia with Lewy bodies.
Cognition Therapeutics (NASDAQ: CGTX) announced positive results from the futility analysis of its Phase 2 'MAGNIFY' trial for zervimesine (CT1812) in geographic atrophy (GA) secondary to dry age-related macular degeneration.
The analysis of 57 participants who completed 6 months of dosing revealed that zervimesine-treated patients showed slower lesion growth compared to placebo. The study, which enrolled 100 participants total, will conclude in February 2025, with complete analysis expected in Q2 2025.
Additionally, the company reported successful outcomes in other trials: The Phase 2 SHIMMER study in dementia with Lewy bodies (DLB) met its primary endpoint, with zervimesine showing significant improvements over placebo across multiple measures. The Phase 2 SHINE study in Alzheimer's disease also met its safety endpoint, with a biomarker-defined subgroup showing 95% reduction in cognitive decline versus placebo.
Cognition Therapeutics (NASDAQ: CGTX) announced that Mary Hamby, PhD will co-host a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit on February 25-27, 2025 in Boston.
Dr. Hamby will present findings from Cognition's Phase 2 'SHINE' study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. The study revealed that participants with lower levels of p-tau217 protein showed significant response to zervimesine treatment, scoring 95% better on the ADAS-Cog 11 scale and 108% better on the MMSE scale compared to placebo.
The workshop, titled "Patient Stratification for Precision Medicine in Neuroscience," will explore how plasma p-tau217 assays could identify Alzheimer's patients most likely to benefit from therapies addressing beta amyloid, including Cognition's oligomer antagonist zervimesine.
Cognition Therapeutics (NASDAQ: CGTX) has published details of a new manufacturing process for their lead Alzheimer's candidate, zervimesine (CT1812), in the American Chemical Society journal Organic Process Research & Development. The company has filed provisional patent applications for both the chemical process and a preferred polymorphic form of the drug.
The new manufacturing process incorporates high throughput screening and light-induced, continuous flow processing technologies, enabling more efficient and safer synthesis of zervimesine. Notably, researchers have identified a novel crystal form of the drug with enhanced room temperature stability, promising a longer shelf life and improved pharmaceutical properties. This process is expected to support both future clinical studies and potential commercial manufacturing needs if the drug receives approval.
Cognition Therapeutics (NASDAQ: CGTX) announced positive Phase 2 'SHIMMER' study results for zervimesine (CT1812) in treating dementia with Lewy bodies (DLB). The study, involving 130 adults with mild-to-moderate DLB over six months, met its primary safety and tolerability endpoints with significant therapeutic improvements.
Key results showed zervimesine-treated participants performed:
- 86% better on behavioral outcomes (NPI A-L)
- 52% better on activities of daily living
- 91% reduction in cognitive fluctuations
- 62% better motor function
The drug demonstrated effectiveness in reducing hallucinations, delusions, anxiety, and agitation - key DLB symptoms. Care partners reported reduced distress levels, and patients showed improved ability to maintain daily living activities. The treatment exhibited a favorable safety profile with mostly mild to moderate adverse events.
Cognition Therapeutics (NASDAQ: CGTX) announced CEO Lisa Ricciardi's participation in upcoming conferences during JP Morgan Healthcare Conference 2025 week. The company reported significant developments in 2024, including positive topline results from their Phase 2 SHIMMER study in dementia with Lewy body (DLB) patients, which will be presented at the International Lewy Body Dementia Conference in Amsterdam.
The company is preparing for an end-of-Phase 2 meeting with the FDA to review results from their SHINE study in mild-to-moderate Alzheimer's disease. Additionally, they received clearance for the generic name 'zervimesine' for their candidate CT1812.
Ricciardi will participate in the Longwood Healthcare Leaders Stanford Summit on January 11, 2025, and the Sachs 8th Annual Neuroscience Innovation Forum on January 12, 2025, both in San Francisco.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
